eli lilly tirzepatide cease and desist letter Issues Cease-And-Desist Letters to Compounders Over Weight-Loss Drug Copies As Shortage Resolves Novo sues Lilly, claiming misleading

While there are certainly some gaps present within this system (e.g., no formally established non-responder protocol, no previously published tapering pathway, etc.) the patient will need to take on the responsibility of seeking out information to ensure their needs are met

The FDA-approved prescribing information specifies that tirzepatide should be administered once weekly on the same day each week, at any time of day, with or without meals

References Michaelides C

doi:10.1016/S0140-6736(21)01324-6Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes

From the abstract: - Zoungas et al, JASN 2025 The GFR results are stunning